Neurology in Biological Technology
Navigation Links
Neurology in Biological Technology
... disease at the 2009 American Academy of neurology meeting in Seattle, WA. The NuroPro tests help ... Marcopoulou, M.D., Assistant Professor of neurology at the University of Thessaly, Greece, gave a ... includes Stanley H. Appel, M.D. Chair of neurology at Methodist Neurological Research Institute in ...
... industry with specific expertise in building neurology assets for success. The two will serve in ... and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical ... corporate development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical ...
... Fahn, M.D., the H. Houston Merritt Professor of neurology and Director of the Center for Parkinson's ... is led by Lucien Cte, M.D., Professor of neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of neurology at Columbia University. "With a disease like ...
... data from this trial next year," said Dr. Mark Freedman, Professor of neurology at the University of Ottawa and Director of the MS Research Clinic at the ... with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to ...
... et al. Neurogastroenterol Motil 2004; 16: 383-394,5 (5) Gimbel JS et al. neurology 2003; 60: 927-934 (6) Watson CP et al. neurology 1998; 50 : 1837-1841 (7) Staahl C et al. Differential effect of opioids ...
... and the burden on caregivers," said study investigator, Daniel Murman, M.D., M.S., Associate Professor and Director, Memory Disorders and Behavior neurology Program with the Department of Neurological Sciences at the University of Nebraska Medical Center . "This information shows that not only are AD ...
... candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic ...
... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...
... and T cells. The results of phase II and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the European Journal of neurology (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types ...
... at the University of California, San Diego . Prior to that, he held research positions at the Neuropsychology Laboratory at the Salk Institute, the neurology Department at the Medical School of the University of California at Irvine , and the Cognitive Psychophysiology Laboratory at the University ...
... of living with uncontrolled seizures," said lead study author Professor Peter Halasz, MD, PhD, National Institute of Psychiatry and Neurology, neurology Department, Budapest. "Vimpat(R) showed significant efficacy versus placebo in a challenging clinical trial patient population." In the study, ...
... needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health. About Janssen Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., based in ...
... to seek stem cell treatments," said Dr. Olle Lindvall, co-chair of the ISSCR task force that developed the guidelines and professor in clinical neurology at the University of Lund. "Stem cell research holds tremendous promise for the development of novel therapies for many serious diseases. However, ...
... Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private ...
... and easy access to daily online first research published across The Lancet journals (The Lancet, The Lancet Infectious Diseases, The Lancet neurology and The Lancet Oncology). - Free access to exclusive online-only editorial analysis of how the most important published research impacts ...
... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...
... Faculty of Medicine, Department of Neurology and Neurosurgery, and Department of Medicine, McGill University, and member of the Attending Staff in neurology at Sir Mortimer B. Davis - Jewish General Hospital, in Montreal, Canada. "This proof-of-concept gives us great hope that biospectroscopy will offer a ...
... industry with specific expertise in building neurology assets for success. The two will serve in ... and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical ... corporate development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical ...
... Fahn, M.D., the H. Houston Merritt Professor of neurology and Director of the Center for Parkinson's ... is led by Lucien Cte, M.D., Professor of neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of neurology at Columbia University. "With a disease like ...
Avicena Appoints Dr. M. Flint Beal to Board of Directors
... professor and chairman of the department of neurology and neuroscience at the Weill Medical College at Cornell University, and director of neurology at New York Presbyterian Hospital. Prior to Cornell, Dr. Beal was the professor of neurology at the Harvard Medical School and chief of the ...NeurogesX Reports Second Quarter 2008 Results
... - Phase 1 clinical trial of NGX-1998 initiated - Journal neurology published positive Phase 3 data on NGX-4010 in HIV-DSP SAN MATEO, ... Phase 2 study in 2009. During the second quarter of 2008, the journal neurology published data from NeurogesX' Phase 3 pivotal trial (C107) in patients ...... data from this trial next year," said Dr. Mark Freedman, Professor of neurology at the University of Ottawa and Director of the MS Research Clinic at the ... with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to ...
Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
... it to market. Dr. Katz also served as Professor of Ophthalmology, neurology and Neurosurgery, and as the Chairman of the Department of Ophthalmology ... University of California at San Francisco after completing residencies in neurology at Harvard Medical School and in Ophthalmology at Tufts-New England ...Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
... led by Dr. Steven Hersch, were published in the January 24, 2006 issue of neurology and showed that HD-02 suppressed an oxidative damage marker, 8OH2DG, which ... General Hospital, were published in the January 24, 2006 issue of neurology and showed that HD-02 suppressed a Huntington's disease marker. Some ...Amarin Signs Agreement to Acquire Ester Neurosciences
... Adds Promising Phase II neurology Candidate $8.1 Million Financing in Connection With Acquisition ... advancing Ester's programs along with our existing development pipeline in neurology and cardiovascular disease." Eli Hazum, Chief Executive Officer of Ester ...Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
... residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert was certified by the American Board of neurology and Psychiatry. He holds an M.D. degree from the University of Sao Paulo ...... et al. Neurogastroenterol Motil 2004; 16: 383-394,5 (5) Gimbel JS et al. neurology 2003; 60: 927-934 (6) Watson CP et al. neurology 1998; 50 : 1837-1841 (7) Staahl C et al. Differential effect of opioids ...
... and the burden on caregivers," said study investigator, Daniel Murman, M.D., M.S., Associate Professor and Director, Memory Disorders and Behavior neurology Program with the Department of Neurological Sciences at the University of Nebraska Medical Center . "This information shows that not only are AD ...
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
... stem cell-based screens and assays. Dr. Lennart Mucke is the director of the Gladstone Institute of Neurological Disease, and a professor of neurology and Neuroscience at UCSF. His research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on ...... candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic ...
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
... iPS technology to the development of new therapeutics for unmet medical needs. We will look to Dr. Goodman's extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said ...Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
... specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com . FORWARD-LOOKING STATEMENTS This press release ...NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
... and commercializing novel pain management therapies, announced today the presentation of two posters at the 61st Annual American Academy of neurology (AAN) meeting in Seattle, Washington. These posters, titled "Neurologic Safety of Treatment with NGX-4010, a High-Concentration Capsaicin Patch, in ...Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...Medivation Announces Upcoming Scientific Presentations at Medical Conferences
... MDV3100 on Sunday, April 26, at 4:00 p.m. Central Time (POD17. Prostate Cancer: Advanced Dimebon 61st American Academy of neurology (AAN) Annual Meeting, April 25 - May 2, Seattle Two poster presentations featuring Dimebon that will take place on: ...... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...
Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
... Immunex Corporation from 1999 - 2001. In that capacity, he managed the discovery, development, manufacture and marketing for Immunex oncology and neurology products. Mr. Parker received his undergraduate degree in Biological Sciences from the University of Chicago , an MBA from the University of ...Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices
... devices in the industry." About Alpine Biomed Alpine Biomed is a global leader in specialty diagnostic devices for the gastroenterology and neurology clinical markets. The company produces diagnostic tools used for gastroesophageal reflux disease (GERD), commonly referred to as acid reflux disease, ...... and T cells. The results of phase II and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the European Journal of neurology (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types ...
... at the University of California, San Diego . Prior to that, he held research positions at the Neuropsychology Laboratory at the Salk Institute, the neurology Department at the Medical School of the University of California at Irvine , and the Cognitive Psychophysiology Laboratory at the University ...
... of living with uncontrolled seizures," said lead study author Professor Peter Halasz, MD, PhD, National Institute of Psychiatry and Neurology, neurology Department, Budapest. "Vimpat(R) showed significant efficacy versus placebo in a challenging clinical trial patient population." In the study, ...
Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
... pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com . (Logo: ...Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
... is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private Securities ...Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
... of Cincinnati , his M.D. from Vanderbilt University and his neurosurgical training at Baylor College of Medicine . Dr. Waltz also had training in neurology at The National Hospital for Neurological Diseases and in Neuropathology at Oxford University , both in the U.K. About Peregrine ...... needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health. About Janssen Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., based in ...
Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
... pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com . About Dow Dow Pharmaceutical Sciences, ....... to seek stem cell treatments," said Dr. Olle Lindvall, co-chair of the ISSCR task force that developed the guidelines and professor in clinical neurology at the University of Lund. "Stem cell research holds tremendous promise for the development of novel therapies for many serious diseases. However, ...
Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
... 37 per cent. Out of the 260 cancer compounds in clinical development in Europe, Denmark accounts for 17 per cent of the European pipeline. neurology (15 per cent) and inflammation/autoimmune diseases (14 per cent) are the fields with second and third most Danish compounds in clinical trials. ...ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
... About Avineuro Pharmaceuticals, Inc.: Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug ...... Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private ...
... and easy access to daily online first research published across The Lancet journals (The Lancet, The Lancet Infectious Diseases, The Lancet neurology and The Lancet Oncology). - Free access to exclusive online-only editorial analysis of how the most important published research impacts ...
Global Psychiatrists Unite to Improve Services in Mental Health
... Dr Wolfgang Fleischhacker, Medical University Innsbruck, Austria Dr Marcelo Cetkovich-Bakmas, the Department of Psychiatry, Institute of Cognitive neurology (INECO), and the Department of Psychiatry, Institute of Neurosciences, Favaloro Foundation, Buenos Aires, Argentina Dr Marc De Hert, University ...... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...
Dr. Yong Shi awarded NSF grant
... on the project are Professor Sundeep Mangla (M. D., Director of Interventional Neuroradiology , Associate Professor of Radiology, Neurosurgery, and neurology ) and Professor Ming Zhang (M.D, Assistant Professor, Dept of Anesthesiology), both from SUNY Downstate Medical Center at Brooklyn, New York. ...... Faculty of Medicine, Department of Neurology and Neurosurgery, and Department of Medicine, McGill University, and member of the Attending Staff in neurology at Sir Mortimer B. Davis - Jewish General Hospital, in Montreal, Canada. "This proof-of-concept gives us great hope that biospectroscopy will offer a ...
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...Other ContentsvaricellavaricellavesiclevesiclevesiclevesiclefeverfeverfeverfeverfeverfeverfeverfeveryellowyellowyellowyellowyellowyellowyellowyellowsystemsystemsystemsystemsystemsystemsystemsystemsystemsystemvestibularvestibularstomatitisstomatitisvesicularvesicularOther TagsTransferTransferTransferTransferTransferTransferTrypsinTrypsin
(Date:12/16/2009)... IgeaCare Solutions Inc. is pleased to ... healthcare communications company previously operating as IgeaCare Systems ... move forward under new leadership and funding. ,, ... to the position of Chief Executive Officer. Under ... providing a superior servicing and support model; fast ...
(Date:12/16/2009)... 16 European Union (EU) member ... borders, which are increasingly subjected to unauthorised ... in advanced technology security and IT-based systems ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, New analysis ... Border Security Market Assessment - European ...
(Date:12/15/2009)... Springer has just signed an agreement with the British ... an affiliation with the journal Biogerontology for ... will appoint one member of the Biogerontology ... issue annually. Springer will sponsor the society and ... Biogerontology on www.springerlink.com . , Biogerontology ...
Breaking Biology News(10 mins):IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3No major role for fish in the prevention of heart failure 58482 1No major role for fish in the prevention of heart failure 58482 2No major role for fish in the prevention of heart failure 58482 3Combining sun sand and science in the Bahamas 10172 1Combining sun sand and science in the Bahamas 10172 2Combining sun sand and science in the Bahamas 10172 3Spallation Neutron Source first of its kind to reach megawatt power 10168 1Spallation Neutron Source first of its kind to reach megawatt power 10168 2(Date:12/16/2009)... the families of sick and dying hospitalized children ask ... How do pediatricians respond to such personal requests? While ... help some patients and families cope with serious illness, ... the families and patients who raise the issue of ... issue of Southern Medical Journal , Brandeis and ...
(Date:12/16/2009)... Medical Solutions, a national healthcare staffing agency, is honored to ... as the company’s Recruiters of the Year in Healthcare Traveler ... second consecutive year that Chris has received such honors and ... ... (PRWEB) December 16, 2009 -- Medical Solutions, a national healthcare ...
(Date:12/16/2009)... -- For ages, people from around the world have ... soothing waters have a reputation that dates back over ... miracles. Now, with the introduction of two bath salt ... the legendary benefits of Dead Sea salt in their ... all-natural Dead Sea salt and essential oils - but ...
(Date:12/16/2009)... -- Dale Buchanan, owner of Supreme Ultimate Fitness ... loss contest for his students in the new year. The ... competing for their own prize or against each other. They ... Tri County Humane Society in Boca Raton, FL. ... January 4 and February 28, 2010 I will donate $10 ...
(Date:12/16/2009)... Better access to patient information could improve care, ... Dec. 16 (HealthDay News) -- U.S. physicians support ... concerns exist about privacy problems, two new studies ... family practice and specialist doctors in Massachusetts found ... (HIE) would improve patient quality of care, 70 ...
Breaking Medicine News(10 mins):Health News:Prayer on the hospital floor 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:Pros and Cons of Electronic Medical Records Weighed 2[0] Prayer on the hospital floor[0] Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients [0] SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea[0] Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter[0] Pros and Cons of Electronic Medical Records Weighed
steadyliteKaryoMAXSilverQuestBacVectorVirologyTransferPureLinkmScriptBaculovirusTrypsinHistidineSupercoiledEtoposideCellSensor
Other Tagsreputation 2reputation 3reputation 4meet 2meet 3meet 4meet 5meet 6identical 2identical 3identical 4identical 5identical 6identical 7identical 8stressed 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |